These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18653231)

  • 1. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
    Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
    Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
    Spänkuch B; Steinhauser I; Wartlick H; Kurunci-Csacsko E; Strebhardt KI; Langer K
    Neoplasia; 2008 Mar; 10(3):223-34. PubMed ID: 18320067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
    Steinhauser I; Langer K; Strebhardt K; Spänkuch B
    J Drug Target; 2009 Sep; 17(8):627-37. PubMed ID: 19591537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
    Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
    J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
    Steinhauser I; Spänkuch B; Strebhardt K; Langer K
    Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
    Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.
    Wagner S; Rothweiler F; Anhorn MG; Sauer D; Riemann I; Weiss EC; Katsen-Globa A; Michaelis M; Cinatl J; Schwartz D; Kreuter J; von Briesen H; Langer K
    Biomaterials; 2010 Mar; 31(8):2388-98. PubMed ID: 20031203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation.
    Kufleitner J; Worek F; Kreuter J
    J Microencapsul; 2010; 27(7):594-601. PubMed ID: 20923399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
    Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
    Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
    Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
    Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Weyermann J; Lochmann D; Georgens C; Zimmer A
    Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
    Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
    Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting.
    Gong G; Zhi F; Wang K; Tang X; Yuan A; Zhao L; Ding D; Hu Y
    Nanotechnology; 2011 Jul; 22(29):295603. PubMed ID: 21673386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
    Wang J; Tao X; Zhang Y; Wei D; Ren Y
    Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
    Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
    J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nanoparticle for tumor targeted delivery of oligomers.
    Liu X; Wang Y; Hnatowich DJ
    Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.